iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

For its Unit III, Aurobindo Pharma has received an EIR report

7 Sep 2023 , 01:00 PM

The United States Food and Drug Administration (US FDA) conducted an inspection of the Company’s Unit III, a Formulation manufacturing facility located at Bachupally Village, Medchal Malkajgiri District, Telangana, from July 14 to July 21, 2023, according to Aurobindo Pharma.

The facility has been labeled as ‘Voluntary Action Indicated’ (VAI) in an Establishment Inspection Report that has just been given to the Unit.

For feedback and suggestions, write to us at editorial@iifl.com

Aurobindo Pharma - Wikipedia

Related Tags

  • Aurobindo Pharma
  • EIR Report
  • USFDA
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.